Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutic AIDS vaccines.

A S Bourinbaiar1, R S Root-Bernstein, R Abulafia-Lapid

  • 1Immunitor USA Inc., College Park, MD 20740, USA. info@immunitor.com

Current Pharmaceutical Design
|June 22, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An atomic force microscopy study in the detection of hepatitis B surface antigen by enzyme-linked immunosorbent assay.

Journal of immunoassay & immunochemistry·2011
Same author

Novel inhibitors of HIV discovered among existing classes of pharmaceutical compounds indicated for unrelated clinical indications.

Current pharmaceutical design·2009
Same author

Peptide therapy for anti-CD4 autoimmunity in HIV-1 infection: toward the development of an autoimmune animal model.

Vaccine·2009
Same author

Molecular epidemiology of the hepatitis C virus in Western Siberia.

Journal of medical virology·2005
Same author

Sorbicillactone A: a structurally unprecedented bioactive novel-type alkaloid from a sponge-derived fungus.

Progress in molecular and subcellular biology·2005
Same author

Effect of an oral therapeutic HIV-1 vaccine on AIDS patients with CD4 count above 250 cells/mm3.

Acta virologica·2004

Conventional therapeutic vaccines for human immunodeficiency virus (HIV) show limited clinical benefit despite inducing immune responses. Unconventional vaccines utilizing allo- or self-antigens show promise for clinical improvement in HIV treatment.

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Diseases

Background:

  • Therapeutic vaccines for human immunodeficiency virus (HIV) are explored as alternatives to antiretroviral therapy.
  • Conventional therapeutic HIV vaccines aim to modulate the immune response in infected individuals.
  • Early immunotherapeutic trials for AIDS began in 1983, with numerous conventional vaccine trials conducted since.

Purpose of the Study:

  • To evaluate the clinical efficacy of conventional versus unconventional therapeutic vaccines for HIV.
  • To investigate the role of allo- or self-antigens in successful HIV therapeutic vaccination.
  • To advocate for diversification in HIV vaccine research strategies.

Main Methods:

  • Review of historical therapeutic vaccine trials for HIV/AIDS.

Related Experiment Videos

  • Analysis of vaccine-induced immune responses versus clinical outcomes.
  • Comparison of conventional vaccines with unconventional approaches involving allo- and autologous vaccination.

    • Main Results:

    • Conventional therapeutic HIV vaccines elicit HIV-specific immune responses but rarely clinical improvement.
    • Apparent clinical benefits were observed with unconventional vaccines containing non-HIV antigens (allo- or self-antigens).
    • These successful unconventional vaccines were derived from blood or cell cultures of HIV carriers.

    Conclusions:

    • The current focus on conventional HIV vaccines with limited clinical efficacy needs re-evaluation.
    • Unconventional vaccination strategies incorporating allo- or self-antigens warrant further investigation for HIV treatment.
    • Future HIV therapeutic vaccine research should explore immune tolerance induction and alternative approaches.